C
Cappella Medical Devices
Cappella Medical Devices develops novel solutions for the treatment of complex coronary artery disease and bifurcation vascular disease.
About Cappella Medical Devices
Founded in 2004 by Dr. Antonio Colombo and Dr. Ascher Shmulewitz, Cappella Medical Devices carved a niche in the complex field of coronary artery disease, specifically focusing on bifurcation lesions where a main coronary artery and a side branch artery are both affected. The company's operations are headquartered in Galway, Ireland, with a U.S. base in Westford, Massachusetts. The business was established to address the challenges interventional cardiologists face when treating these complex cases, which account for up to 30% of all percutaneous coronary intervention (PCI) procedures.
The core of Cappella's offering is the Sideguard® Coronary Sidebranch Stent and Delivery System. This product is a self-expanding nitinol stent designed to be placed in the side branch of a coronary artery first. Its unique trumpet-shaped flare at the proximal end is engineered to provide full coverage of the side branch opening (ostium), a critical area prone to complications. This 'side branch first' approach allows the cardiologist to then treat the main vessel with their preferred conventional stent, preserving access to the side branch and minimizing trauma to the vessel walls that can lead to restenosis. The delivery system features a proprietary split-sheath technology to ensure precise placement. The nitinol material provides a constant outward radial force, promoting continuous apposition to the vessel wall and positive remodeling over time.
Cappella Medical Devices operates in the interventional cardiology market, serving hospitals and cardiac catheterization labs. Its business model revolves around the development, manufacturing, and sale of its specialized stent systems. Revenue is generated through the distribution of the CE Mark-approved Sideguard system in Europe and South America. The company secured significant funding to support its growth, including a $17.3 million Series C round in 2009, which facilitated the European launch of the Sideguard stent and expanded R&D and manufacturing in Galway. In 2014, Cappella Medical Devices Ltd. was renamed ArraVasc Ltd., reflecting an expansion into the peripheral vascular market.
Source: Dealroom company dataNews
Open roles
Cappella Medical Devices in the Galway ecosystem
The Cappella Medical Devices office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
PolyTechnos Venture Partners
Series B and later3 investors entered at this stage
Act Venture Capital
Fountain Healthcare Partners
Kreos Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cappella Medical Devices on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cappella Medical Devices on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


